[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572619":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":43,"responsibleParty":61,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":32,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Centre Hospitalier de Saint-Denis","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"sickle cell patients over 15 and a half years old","EXPERIMENTAL","sickle cell patients over 15 and a half years old with SS or Sβ0 phenotype",[13],"Biological: Measurement of AHSP concentration",{"label":15,"type":6,"description":16,"interventionNames":17},"control patients over 15 and a half years old","control patients over 15 and a half years old without hemoglobin abnormalities, recruited at the hospital",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"pediatric sickle cell patients (aged between 3 and 15 and a half years)","pediatric sickle cell patients (aged between 3 and 15 and a half years) with SS or Sβ0 phenotype",[13],{"label":23,"type":6,"description":24,"interventionNames":25},"pediatric control patients (aged between 3 and 15 and a half years)","pediatric control patients (aged between 3 and 15 and a half years) without hemoglobin abnormalities, recruited at the hospital",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","Measurement of AHSP concentration","Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.\n\nThe 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.",[15,23,19,9],null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":37},"Stéphanie NGO, Coordinating Investigator","CONTACT","stephanie.ngo@ch-stdenis.fr","01 42 35 60",{"name":40,"role":36,"phone":41,"phoneExt":42,"email":41},"Stéhanie COSSEC, Project Coordinator","stephanie.cossec@ghtpdfr.fr","01.42.35.61.40",[44],{"facility":5,"status":45,"city":46,"state":32,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Saint-Denis","93200","France","FR",{"type":51,"coordinates":52},"Point",[53,54],2.35387,48.93564,{"lat":54,"lon":53},[57],{"name":58,"role":36,"phone":59,"phoneExt":32,"email":60},"Stéphanie NGO","0142356140","stephanie.ngod@ch-stdenis.fr",{"type":62,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[64],{"name":65,"class":6},"Inserm U955","100572619","pilot-study-ahsp-as-a-biomarker-of-sickle-cell-disease-in-a-population-of-adults-and-children-100572619",false,"NCT06735625","Pilot Study \"AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children\"","AHSPDREP","Inclusion Criteria:\n\nInclusion Criteria for Sickle Cell Patients\n\n1. Adults: \\> 15 years and 6 months\n2. Pediatrics: ≥ 3 years and ≤ 15 years and 6 months\n3. Known SS or Sβ0 phenotypes\n\nInclusion Criteria for Control Patients.\n\n1 -Adults: \\> 15 years and 6 months \u002FPediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration\n\n-Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder\n\n4-Blood sample planned as part of medical care\n\nExclusion Criteria:\n\n1. Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients)\n2. Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients)\n3. Transfusion less than 3 months ago\n4. Chronic active viral disease: hepatitis B, C, HIV\n5. Current infections or known inflammatory pathologies\n6. Known hyper or hypothyroidism or subject treated with levothyroxine\n7. Active tumor pathology or remission for less than 5 years\n8. Oral corticosteroid therapy in progress\n9. Participation in interventional biomedical research\n10. Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor.\n11. Non-affiliation to a social security system","ALL","3 Years",{"count":76,"type":77},100,"ESTIMATED","INTERVENTIONAL",[80],"NA","Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients",[83],"in Relation to Sickle Cell Disease",[85,86,87,88],"AHSP","Sickle Cell Disease","SS Phenotype","Sβ0 Phenotype","2025-03-28",{"date":91,"type":92},"2025-04-02","ACTUAL",{"date":94,"type":92},"2025-03-06",{"date":96,"type":77},"2027-01-20",{"name":5,"class":6},1]